SeaStar Medical's Upcoming Presentation at NobleCon21
SeaStar Medical Holding Corporation (NASDAQ: ICU) is gearing up for an exciting event as it prepares to present at the prestigious NobleCon21 investor conference. This conference, organized by Noble Capital Markets, will take place at the Executive Education Complex of Florida Atlantic University, bringing together key stakeholders in the healthcare sector.
Leadership Insight
Eric Schlorff, the Chief Executive Officer of SeaStar Medical, will take the stage at NobleCon21, sharing insights into the company’s innovative approach to healthcare. Schlorff’s leadership and vision are crucial as SeaStar continues to push the boundaries of what is possible in treating critically ill patients experiencing organ failure.
About SeaStar Medical's Innovative Therapies
At the heart of SeaStar Medical's mission is a dedication to transforming healthcare for those facing severe challenges, including potential organ failure. The company’s QUELIMMUNE (SCD-PED) therapy stands as a significant milestone in its pursuit of advanced medical solutions. This therapy—a result of rigorous research and development—utilizes SeaStar's patented Selective Cytopheretic Device (SCD) technology.
FDA Approval: A Major Milestone
In 2024, the QUELIMMUNE (SCD-PED) therapy received approval from the U.S. Food and Drug Administration (FDA), marking a historic achievement for SeaStar Medical. This recognition is particularly noteworthy as it positions QUELIMMUNE as the only FDA-approved product specifically addressing life-threatening acute kidney injury (AKI) in pediatric patients experiencing septic conditions.
Advancements and Clinical Trials
SeaStar Medical continues to innovate with its Selective Cytopheretic Device (SCD) technology, which has earned Breakthrough Device Designation for multiple therapeutic indications. This designation aims to streamline the approval process and support favorable reimbursement strategies upon commercial launch. Currently, the company is conducting pivotal trials of its SCD therapy in adult patients suffering from AKI, a critical condition affecting many individuals annually.
A Commitment to Better Outcomes
The ongoing clinical trials and innovative solutions provided by SeaStar Medical aim to improve patient outcomes significantly. The company acknowledges that AKI related to sepsis is a severe issue impacting over 200,000 adults in the U.S. each year. By investing in research and development, SeaStar aims to address this urgent healthcare challenge effectively.
Register and Attend NobleCon21
Investors and interested parties are encouraged to attend the upcoming conference to learn about SeaStar Medical's endeavors first-hand. Those attending can register for the event and use the code ICUNOBLECON to access the SeaStar Medical participation rate. The insights shared during this conference are anticipated to shed light on the future of organ failure treatments and the impact of SeaStar Medical's technologies.
Accessing the Presentation
For those unable to attend, a replay of the presentation will be available after the event. This presents an excellent opportunity to catch up on the discussion around SeaStar Medical’s latest advancements and contributions to healthcare, available for viewing on the company’s website for 30 days post-presentation.
Company Overview and Contact Information
SeaStar Medical is at the forefront of medical innovation, focusing on critical care solutions that change lives. The company is committed to advancing therapies that treat and potentially reverse the effects of organ failure. For more information about SeaStar Medical and its product offerings, visit the company’s website or connect via social media platforms.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
Frequently Asked Questions
What is SeaStar Medical focusing on during the conference?
SeaStar Medical will present its innovative therapies designed for critically ill patients, particularly concerning organ failure.
Who is the CEO of SeaStar Medical?
Eric Schlorff is the Chief Executive Officer leading SeaStar Medical.
What is the significance of the QUELIMMUNE therapy?
QUELIMMUNE (SCD-PED) therapy is the first FDA-approved treatment for life-threatening acute kidney injury in pediatric patients.
Why should investors attend NobleCon21?
Investors can gain valuable insights into SeaStar Medical's growth strategies and new developments in healthcare at the conference.
How can I access the presentation if I miss it?
A replay of the presentation will be available on the company's website for up to 30 days following the conference.
